Food Addiction Screening: What the Questionnaire Cannot Measure

A positive craving questionnaire documents what a patient reports. It says nothing about insulin, energy expenditure or autonomic tone, and those are the variables a clinician can actually follow.

Food addiction screening is scored with a self-report instrument, not a biomarker. Pooled across 272 studies, prevalence on the standard scale is 20%, and it reaches 55% in samples where binge eating is already diagnosed. Whether the construct is valid remains open; many defining features of drug addiction do not appear with food, even if the two share neural machinery. A positive screen therefore documents an experience accurately and a disease provisionally. For the clinician, the useful question is what sits underneath it that can be measured and followed. The video Your Sugar Craving Has a Schedule lays out the gut-to-brainstem route; the screening and workup implications follow.

What does a food addiction screen measure, and who was it tested on?

The pooled prevalence carries its own fine print. Clinical samples scored higher than community samples, as expected for a tool used inside eating-disorder programs. Age coverage is thin: two included studies enrolled only children, and none enrolled only older adults. A geriatric patient with a positive score is being compared against almost no one.

In the cohort where the microbiome was sequenced alongside the scale, 19 of 105 women screened positive. Seventeen of those 19 had obesity, against 34 of the 86 who screened negative, and mean BMI ran 35.6 with the label against 29.1 without it. The instrument tracked adiposity more than anything else measured. Alpha diversity did not differ between the groups, which is worth knowing before a patient arrives with a direct-to-consumer stool report as supporting evidence.

Why the framing changes management

The distinction is clinical rather than semantic. If the pattern is addiction in the strict sense, management is abstinence and indefinite relapse prevention. If it is a preference written by exposure, management is changing the exposure and allowing time. The evidence favors the second model more than most clinicians expect.

Normal-weight adults given a daily high-fat, high-sugar snack for eight weeks showed lower preference for low-fat food and greater neural response to food, with no relationship to body weight or metabolic parameters. Separately, inpatients offered ultra-processed and unprocessed diets matched on presented calories, energy density, macronutrients, sugar, sodium and fiber ate 508 kcal a day more on the ultra-processed arm, with the excess coming from carbohydrate and fat and protein intake flat. Weight change tracked intake at r = 0.8.

I spent years delivering eat-less counseling to people whose appetite had been reshaped by the food supply, and I documented the failures as adherence problems. The snack trial is what reframed that for me: preference moved in people whose weight did not. The economic driver belongs in the same note. Refined carbohydrate is the cheapest calorie available because agricultural policy subsidized it, and it is formulated to succeed against the reward circuitry those trials measured.

What does a food addiction questionnaire miss?

A craving history is a reason to measure metabolic and autonomic state, not a substitute for it. Measura [Cardiometabolic and Autonomic Health Analysis] does not score food addiction, sequence stool or treat; it produces measurements that return to the ordering physician.

Insulin sensitivity. In 45 adults who were not habitual sweetener users, sucralose consumed with carbohydrate, but not sucralose alone, reduced insulin sensitivity over two weeks, and taste preference did not change. An adolescent arm was stopped after HOMA-IR rose above 12.9 in two of three participants. A history of sweetened beverages alongside starch justifies laboratory panels that pair insulin with glucose rather than glucose alone.
Measured energy expenditure. When intake is the clinical argument, indirect calorimetry replaces a predictive equation with the patient’s measured resting metabolic rate, which gives calorie counseling a denominator the patient cannot dispute.
Autonomic baseline. Heart rate variability reflects autonomic balance. It is not a readout of vagal gut signaling, and the vagus itself is a weak lever: in 239 patients randomized to reversible vagal blockade or sham, excess weight loss was 24.4% against 15.9% and both co-primary endpoints were missed. HRV documents the terrain those signals travel through.

Who should be tested after a positive food addiction screen?

The reasonable candidates are patients with a positive score and obesity, patients with a binge eating diagnosis, patients whose craving pattern is time-locked and carbohydrate-specific, and patients whose history includes daily sweetened drinks with starchy food. Most will already carry insulin resistance, a mood disorder, disrupted sleep or polypharmacy, which is precisely why no clean trial describes them. Mechanism is the operative evidence tier for this population, and it is sufficient to justify measurement. For context on the denominator, fewer than 7% of US adults are metabolically healthy on the tighter criteria applied to NHANES after 2021, down from fewer than 12.2% on NHANES 2009–2016. In our clinic the figure is under 3%, practice-reported figures from our own population, not trial outcomes, and individual results vary. Formal criteria are outlined in selection criteria.

Reading craving outcomes when a GLP-1 agonist is on board

Semaglutide supplies the strongest human evidence that a gut-derived signal changes food preference. In 72 adults with obesity over 20 weeks, ad libitum intake fell 35%, and after correction for body weight there was no evidence of delayed gastric emptying. At two years, sweet-food craving improvement did not persist while savory craving and craving control did. Craving scores improved in step with weight loss, the eating questionnaire went to a subgroup of 88 on drug and 86 on placebo, and multiplicity was not controlled. Craving response and weight change cannot be separated in that dataset. A pre-treatment metabolic and autonomic baseline gives an independent reference that does not move simply because weight does.

Building it into existing workflow

Craving history fits the dietary and functional review already present in the annual wellness visit. A standing protocol that triggers insulin, measured resting energy expenditure and heart rate variability after a positive screen makes the response reproducible across clinicians; the logic is laid out in making screening reproducible. Results filed as structured data support longitudinal tracking and quality reporting. The patient-facing explanation is in what causes sugar cravings, and the full study-by-study limits are in the Angry Gut companion deep dive for Chapter 24.

Frequently asked questions

Is food addiction a validated diagnosis?

Not yet. It is defined by a self-report scale, pooled prevalence is 20%, and the field has no consensus that the construct is valid, since many hallmark features of drug addiction are absent with food. Treat a positive score as a documented experience that warrants metabolic measurement rather than as a diagnosis that dictates an abstinence model. Review the clinical rationale.

Does a stool microbiome report add anything to a positive screen?

Very little for decision-making. In the sequenced cohort of women, alpha diversity did not differ between those who screened positive and those who did not, and no human study has shown a defined microbial change causing a craving. The measurable questions in these patients are metabolic. The limits of commercial gut testing are covered in intestinal methanogen overgrowth.

Which laboratory measures belong with a positive screen?

Pair insulin with glucose. The sucralose trial found impaired insulin sensitivity only when sweetener arrived with carbohydrate, a change glucose alone may not reveal early. Add measured resting energy expenditure when intake is the counseling focus, and an autonomic baseline where the history suggests broader dysregulation. Interpretation conventions are described in interpreting the report.

Should screening change once a patient starts a GLP-1 agonist?

The screen remains useful, but its trajectory is confounded. In the two-year semaglutide data, craving improvement correlated with weight loss, and sweet craving gains faded by two years. A baseline drawn before therapy, repeated at intervals, separates metabolic change from appetite change. Follow-up cadence for that kind of tracking is covered in chronic care and between-visit monitoring.

How do results reach the chart?

Measura returns results to the ordering physician, who makes any diagnosis and decides management. Filing insulin, resting metabolic rate and heart rate variability as discrete values lets a practice trend them against the craving score over successive visits instead of relying on narrative notes. Integration options are described in getting results into the record.

How do you stop food cravings?

The evidence points to exposure more than willpower. Normal-weight adults given a daily high-fat, high-sugar snack for eight weeks came to like low-fat food less, with no relationship to body weight. If the pattern is a preference written by exposure rather than addiction in the strict sense, management is changing the exposure and allowing time, not abstinence and indefinite relapse prevention. The patient version is what causes sugar cravings.

See how the protocol fits a craving workup

Learn how Measura adds insulin, measured resting metabolic rate and heart rate variability to your practice’s response to a positive food addiction screen.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Praxedes, D. R. S., Silva-Júnior, A. E., Macena, M. L., Oliveira, A. D., Cardoso, K. S., Nunes, L. O., Monteiro, M. B., Melo, I. S. V., Gearhardt, A. N., & Bueno, N. B. (2022). Prevalence of food addiction determined by the Yale Food Addiction Scale and associated factors: a systematic review with meta-analysis. European Eating Disorders Review, 30(2), 85-95. https://doi.org/10.1002/erv.2878
Fletcher, P. C., & Kenny, P. J. (2018). Food addiction: a valid concept?. Neuropsychopharmacology, 43(13), 2506-2513. https://doi.org/10.1038/s41386-018-0203-9
Dong, T. S., Mayer, E. A., Osadchiy, V., Chang, C., Katzka, W., Lagishetty, V., Gonzalez, K., Kalani, A., Stains, J., Jacobs, J. P., Longo, V. D., & Gupta, A. (2020). A distinct brain-gut-microbiome profile exists for females with obesity and food addiction. Obesity, 28(8), 1477-1486. https://doi.org/10.1002/oby.22870
Edwin Thanarajah, S., DiFeliceantonio, A. G., Albus, K., Kuzmanovic, B., Rigoux, L., Iglesias, S., Hanßen, R., Schlamann, M., Cornely, O. A., Brüning, J. C., Tittgemeyer, M., & Small, D. M. (2023). Habitual daily intake of a sweet and fatty snack modulates reward processing in humans. Cell Metabolism, 35(4), 571-584.e6. https://doi.org/10.1016/j.cmet.2023.02.015
Hall, K. D., Ayuketah, A., Brychta, R., Cai, H., Cassimatis, T., Chen, K. Y., Chung, S. T., Costa, E., Courville, A., Darcey, V., Fletcher, L. A., Forde, C. G., Gharib, A. M., Guo, J., Howard, R., Joseph, P. V., McGehee, S., Ouwerkerk, R., Raisinger, K., … Zhou, M. (2019). Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. Cell Metabolism, 30(1), 67-77.e3. https://doi.org/10.1016/j.cmet.2019.05.008
Dalenberg, J. R., Patel, B. P., Denis, R., Veldhuizen, M. G., Nakamura, Y., Vinke, P. C., Luquet, S., & Small, D. M. (2020). Short-term consumption of sucralose with, but not without, carbohydrate impairs neural and metabolic sensitivity to sugar in humans. Cell Metabolism, 31(3), 493-502.e7. https://doi.org/10.1016/j.cmet.2020.01.014
Ikramuddin, S., Blackstone, R. P., Brancatisano, A., Toouli, J., Shah, S. N., Wolfe, B. M., Fujioka, K., Maher, J. W., Swain, J., Que, F. G., Morton, J. M., Leslie, D. B., Brancatisano, R., Kow, L., O’Rourke, R. W., Deveney, C., Takata, M., Miller, C. J., Knudson, M. B., … Billington, C. J. (2014). Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. JAMA, 312(9), 915-922. https://doi.org/10.1001/jama.2014.10540
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity & Metabolism, 23(3), 754-762. https://doi.org/10.1111/dom.14280
Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Garvey, W. T. (2023). Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity, 31(3), 703-715. https://doi.org/10.1002/oby.23673